Seasonal Influenza Vaccines – 5EU Drug Forecast and Market Analysis to 2025

Categories: Drugs by Therapeutic Area, Infectious Diseases Drugs, Pharmaceuticals

Price: $6,995

Description

Seasonal Influenza Vaccines - 5EU Drug Forecast and Market Analysis to 2025

Summary

Influenza, often referred to as the flu, is an acute infection caused by one of the three closely related viruses, designated as influenza Type A, B, and C. The infection’s rapid onset and potential for high morbidity and mortality, particularly in high-risk patient populations such as the elderly and young children, make prompt and effective treatment with antiviral medication very difficult. For these reasons, prophylactic vaccination is the preferred intervention for seasonal influenza.

A quadrivalent formulation of Intanza Intradermal is anticipated to be launched in the EU, following the launch of quadrivalent Fluzone Intradermal in the US. The sales of quadrivalent Intanza Intradermal are expected to increase to $1.5m in 2025. Its growth will be driven by its improved immunogenicity in elderly patients compared to typical influenza vaccines and the increase in the size of Germany’s elderly population.

Scope

- Overview of Seasonal Influenza Vaccines including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in 5EU including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in 5EU from 2015-2025.
- Analysis of the impact of key events as well the drivers and restraints affecting 5EU Seasonal Influenza Vaccines market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Seasonal Influenza Vaccines.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2015-2025 in 5EU.

Table of Contents

1. List of Tables and Figures

2 Introduction

2.1 Catalyst

2.2 Related Reports

2.3 Upcoming Related Reports

3 Disease Overview

3.1 Etiology and Pathophysiology

3.1.1 Etiology

3.1.2 Pathophysiology

3.1.3 Symptoms and Prognosis

4 Disease Management

4.1 Seasonal Influenza Immunization Policy

4.1.1 Immunization Recommendations and Most Frequently Administered Seasonal Influenza Vaccines

4.2 France

4.2.1 Influenza Immunization Recommendations and Policies

4.2.2 Clinical Practice

4.3 Germany

4.3.1 Influenza Immunization Recommendations and Policies

4.3.2 Clinical Practice

4.4 Italy

4.4.1 Influenza Immunization Recommendations and Policies

4.4.2 Clinical Practice

4.5 Spain

4.5.1 Influenza Immunization Recommendations and Policies

4.5.2 Clinical Practice

4.6 UK

4.6.1 Influenza Immunization Recommendations and Policies

4.6.2 Clinical Practice

5 Competitive Assessment

5.1 Overview

5.2 Product Profiles - Major Brands, Inactivated Vaccines

5.2.1 Fluzone Quadrivalent

5.2.2 Fluzone High-Dose

5.2.3 Fluzone Intradermal

5.2.4 Vaxigrip

5.2.5 Fluarix Tetra

5.2.6 Fluvirin

5.2.7 Afluria

5.2.8 Agrippal

5.3 Product Profiles - Major Brands, Inactivated Vaccines (Adjuvanted)

5.3.1 Fluad

5.4 Product Profiles - Major Brands, Live-Attenuated Vaccines

5.4.1 FluMist Quadrivalent

5.5 Product Profiles - Major Brands, Cell Cultured Vaccines

5.5.1 Flublok

5.5.2 Flucelvax

5.6 Other Seasonal Influenza Vaccines

5.6.1 Influvac

5.6.2 Minor Brands

6 Unmet Needs and Opportunity Analysis

6.1 Overview

6.2 Higher Level of Public Awareness and Positive Perception of Influenza Vaccines

6.2.1 Unmet Need

6.2.2 Gap Analysis

6.2.3 Opportunity

6.3 Immunization Policies Targeting Children and Adolescents

6.3.1 Unmet Need

6.3.2 Gap Analysis

6.3.3 Opportunity

6.4 Enhanced Vaccine Efficacy in High-Risk Groups

6.4.1 Unmet Need

6.4.2 Gap Analysis

6.4.3 Opportunity

6.5 Vaccines Leveraging Innovative and Efficient Manufacturing Technologies

6.5.1 Unmet Need

6.5.2 Gap Analysis

6.5.3 Opportunity

6.6 Improving the Cost-Effectiveness of Influenza Vaccines

6.6.1 Unmet Need

6.6.2 Gap Analysis

6.6.3 Opportunity

6.7 Vaccines with Broader Influenza Strain Coverage

6.7.1 Unmet Need

6.7.2 Gap Analysis

6.7.3 Opportunity

6.8 Improved Vaccine Safety Profile

6.8.1 Unmet Need

6.8.2 Gap Analysis

6.8.3 Opportunity

7 Pipeline Assessment

7.1 Overview

7.2 Promising Vaccines in Clinical Development

7.2.1 Seasonal Influenza VLP Vaccine

7.2.2 VN-100

7.2.3 Quadrivalent Seasonal Influenza VLP Vaccine

7.3 Promising Vaccines in Early-Stage Development

7.3.1 FLU-v

7.3.2 M-001

7.3.3 TAK-850

7.3.4 VAX-2012Q

7.4 Other Vaccines in Development Outside the 7MM

8 Market Outlook

8.1 France

8.1.1 Forecast

8.1.2 Key Events

8.1.3 Drivers and Barriers

8.2 Germany

8.2.1 Forecast

8.2.2 Key Events

8.2.3 Drivers and Barriers

8.3 Italy

8.3.1 Forecast

8.3.2 Key Events

8.3.3 Drivers and Barriers

8.4 Spain

8.4.1 Forecast

8.4.2 Key Events

8.4.3 Drivers and Barriers

8.5 United Kingdom

8.5.1 Forecast

8.5.2 Key Events

8.5.3 Drivers and Barriers

9 Appendix

9.1 Bibliography

9.2 Abbreviations

9.3 Methodology

9.4 Forecasting Methodology

9.4.1 Vaccine Coverage

9.4.2 Vaccines Included

9.4.3 Key Launch Dates

9.4.4 Influenza Vaccine Tender System Assumptions

9.4.5 General Pricing Assumptions

9.4.6 Individual Vaccine Assumptions

9.4.7 Pricing of Pipeline Agents

9.5 Primary Research - KOLs Interviewed for this Report

9.6 Primary Research - Prescriber Survey

9.7 About the Authors

9.7.1 Analyst

9.7.2 Therapy Area Director

9.7.3 Epidemiologists

9.7.4 Director of Epidemiology

9.7.5 Global Director of Therapy Analysis and Epidemiology

9.8 About

9.9 Disclaimer

List of Tables

Table 1: Notable Influenza Pandemics

Table 2: Influenza Symptoms

Table 3: Seasonal Influenza Immunization Recommendation Agencies by Country, 2016

Table 4: Immunization Recommendations and Most Frequently Administered Seasonal Influenza Vaccines, 2016

Table 5: Country Profile - France

Table 6: Country Profile - Germany

Table 7: Country Profile - Italy

Table 8: Country Profile - Spain

Table 9: Country Profile - UK

Table 10: Leading Seasonal Influenza Vaccines, 2016

Table 11: Product Profile - Fluzone Quadrivalent

Table 12: Immunogenicity Profile of Fluzone Quadrivalent

Table 13: Local and Systemic AEs of Fluzone Quadrivalent

Table 14: Fluzone Quadrivalent SWOT Analysis, 2016

Table 15: Global Sales Forecast ($m) for Fluzone Quadrivalent, 2015-2025

Table 16: Product Profile - Fluzone High-Dose

Table 17: Immunogenicity of Fluzone High-Dose Compared with Fluzone

Table 18: Local and Systemic AEs of Fluzone High-Dose

Table 19: Fluzone High-Dose SWOT Analysis, 2016

Table 20: Global Sales Forecast ($m) for Fluzone High-Dose, 2015-2025

Table 21: Product Profile - Fluzone Intradermal

Table 22: Comparison of Fluzone Intradermal Quadrivalent Versus Fluzone Intradermal Trivalent

Table 23: Local andsystemic AEs of Fluzone Intradermal Quadrivalent

Table 24: Fluzone Intradermal Quadrivalent SWOT Analysis, 2016

Table 25: Global Sales Forecast ($m) for Fluzone/Intanza Intradermal, 2015-2025

Table 26: Product Profile - Vaxigrip

Table 27: Cumulative Incidence of Influenza Infection in Children

Table 28: Local and Systemic AEs of Vaxigrip

Table 29: Vaxigrip SWOT Analysis, 2016

Table 30: Global Sales Forecast ($m) for Vaxigrip, 2015-2025

Table 31: Product Profile - Fluarix Tetra

Table 32: Immunogenicity Profile of Fluarix Tetra

Table 33: Local and Systemic AEs of Fluarix Tetra

Table 34: Fluarix Tetra SWOT Analysis, 2016

Table 35: Global Sales Forecast ($m) for Fluarix Tetra, 2015-2025

Table 36: Product Profile - Fluvirin

Table 37: Immunogenicity of Fluvirin in Adults

Table 38: Local and Systemic AEs of Fluvirin

Table 39: Fluvirin SWOT Analysis, 2016

Table 40: Global Sales Forecast ($m) for Fluvirin, 2015-2025

Table 41: Product Profile - Afluria

Table 42: Immunogenicity of Afluria in Adults

Table 43: Local and Systemic AEs of Afluria

Table 44: Afluria SWOT Analysis, 2016

Table 45: Global Sales Forecast ($m) for Afluria, 2015-2025

Table 46: Product Profile - Agrippal

Table 47: Immunogenicity of Agrippal

Table 48: Local and Systemic AEs of Agrippal

Table 49: Agrippal SWOT Analysis, 2016

Table 50: Global Sales Forecast ($m) for Agrippal, 2015-2025

Table 51: Product Profile - Fluad

Table 52: Immunogenicity Comparison of Fluad Versus Agriflu

Table 53: Local and Systemic AEs of Fluad

Table 54: Fluad SWOT Analysis, 2016

Table 55: Global Sales Forecast ($m) for Fluad, 2015-2025

Table 56: Product Profile - FluMist Quadrivalent

Table 57: Noninferiority of FluMist Quadrivalent Compared with FluMist Trivalent

Table 58: AEs of FluMist Quadrivalent

Table 59: FluMist Quadrivalent SWOT Analysis, 2016

Table 60: Global Sales Forecast ($m) for FluMist Quadrivalent, 2015-2025

Table 61: Product Profile - Flublok

Table 62: Immunogenicity of Flublok compared with Fluzone and Fluzone High-Dose

Table 63: Local and Systemic AEs of Flublok

Table 64: Flublok SWOT Analysis, 2016

Table 65: Global Sales Forecast ($m) for Flublok, 2015-2025

Table 66: Product Profile - Flucelvax

Table 67: Immunogenicity of Flucelvax

Table 68: Local and Systemic AEs of Flucelvax

Table 69:Flucelvax SWOT Analysis, 2016

Table 70: Global Sales Forecast ($m) for Flucelvax, 2015-2025

Table 71: Summary of Other Marketed Seasonal Influenza Vaccines, 2016

Table 72: Unmet Need and Opportunity in Seasonal Influenza Vaccines, 2016

Table 73: Seasonal Influenza Vaccines - Late-Stage Pipeline, 2016

Table 74: Quadrivalent Versions of Marketed Vaccines

Table 75: Product Profile - Seasonal Influenza VLP Vaccine

Table 76: Seasonal Influenza VLP Vaccine SWOT Analysis, 2016

Table 77: Global Sales Forecast ($m) for Seasonal Influenza VLP Vaccine, 2015-2025

Table 78: Product Profile - VN-100

Table 79: Comparison of Immunogenicity Profile of VN-100 and Subcutaneous Standard Vaccine

Table 80: Frequency of Local and Systemic AEs of VN-100 Compared with a Comparator Subcutaneous Vaccine

Table 81: VN-100 SWOT Analysis, 2016

Table 82: Global Sales Forecast ($m) for VN-100, 2015-2025

Table 83: Product Profile - Quadrivalent Seasonal Influenza VLP Vaccine

Table 84: Quadrivalent Seasonal Influenza VLP Vaccine SWOT Analysis, 2016

Table 85: Global Sales Forecast ($m) for Quadrivalent Seasonal Influenza VLP Vaccine, 2015-2025

Table 86: Promising Vaccines in Early-Stage Development, 2016

Table 87: Summary of Seasonal Influenza Vaccines in Development Outside the 7MM, 2016

Table 88: Sales Forecasts ($m) for Seasonal Influenza Vaccines in France, 2015 -2025

Table 89: Key Events Impacting Sales for Seasonal Influenza in France, 2015?2025

Table 90: France Seasonal Influenza Vaccines Market - Drivers and Barriers, 2015?2025

Table 91: Sales Forecasts ($m) for Seasonal Influenza Vaccines in Germany, 2015 -2025

Table 92: Key Events Impacting Sales for Seasonal Influenza in Germany, 2015?2025

Table 93: Germany Seasonal Influenza Vaccines Market - Drivers and Barriers, 2015?2025

Table 94: Sales Forecasts ($m) for Seasonal Influenza Vaccines in Italy, 2015-2025

Table 95: Key Events Impacting Sales for Seasonal Influenza in Italy, 2015?2025

Table 96: Italy Seasonal Influenza Vaccines Market - Drivers and Barriers, 2015?2025

Table 97: Sales Forecasts ($m) for Seasonal Influenza Vaccines in Spain, 2015 -2025

Table 98: Key Events Impacting Sales for Seasonal Influenza in Spain, 2015?2025

Table 99: Spain Seasonal Influenza Vaccines Market - Drivers and Barriers, 2015?2025

Table 100: Sales Forecasts ($m) for Seasonal Influenza Vaccines in the UK, 2015-2025

Table 101: Key Events Impacting Sales for Seasonal Influenza in the UK, 2015?2025

Table 102: UK Seasonal Influenza Vaccines Market - Drivers and Barriers, 2015?2025

Table 103: Key Launch Dates

Table 104: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

Figure 1: Influenza Virus Structure

Figure 2: Seasonal Influenza Vaccines - Phase II/Phase III Pipeline, 2016

Figure 3: Competitive Assessment of the Late-Stage Pipeline Vaccines for Seasonal Influenza, 2015-2025

Figure 4: Sales of Seasonal Influenza Vaccines by Class in France, 2015 and 2025

Figure 5: Sales of Seasonal Influenza Vaccines by Class in Germany, 2015 and 2025

Figure 6: Sales of Seasonal Influenza Vaccines by Class in Italy, 2015 and 2025

Figure 7: Sales of Seasonal Influenza Vaccines by Class in Spain, 2015 and 2025

Figure 8: Sales of Seasonal Influenza Vaccines by Class in the UK, 2015 and 2025